Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund acquired 10,000 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were acquired at an average cost of $4.88 per share, with a total value of $48,800.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Wednesday, June 5th, Armistice Capital Master Fund bought 15,000 shares of Cerecor stock. The stock was purchased at an average price of $4.81 per share, with a total value of $72,150.00.
  • On Friday, May 31st, Armistice Capital Master Fund acquired 51,000 shares of Cerecor stock. The stock was bought at an average price of $4.71 per share, with a total value of $240,210.00.
  • On Tuesday, May 28th, Armistice Capital Master Fund acquired 29,000 shares of Cerecor stock. The stock was bought at an average price of $5.02 per share, with a total value of $145,580.00.
  • On Friday, May 17th, Armistice Capital Master Fund bought 10,000 shares of Cerecor stock. The shares were acquired at an average cost of $5.18 per share, for a total transaction of $51,800.00.
  • On Tuesday, May 14th, Armistice Capital Master Fund purchased 20,000 shares of Cerecor stock. The stock was purchased at an average cost of $4.97 per share, for a total transaction of $99,400.00.
  • On Wednesday, March 27th, Armistice Capital Master Fund bought 50,000 shares of Cerecor stock. The stock was bought at an average cost of $5.47 per share, for a total transaction of $273,500.00.

Shares of NASDAQ:CERC traded up $0.24 during midday trading on Friday, reaching $5.95. 1,505 shares of the company’s stock traded hands, compared to its average volume of 96,283. The company has a quick ratio of 0.91, a current ratio of 0.95 and a debt-to-equity ratio of 0.62. Cerecor Inc has a one year low of $2.71 and a one year high of $7.65.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $5.41 million for the quarter, compared to the consensus estimate of $4.85 million. Cerecor had a negative return on equity of 120.67% and a negative net margin of 226.50%. On average, analysts forecast that Cerecor Inc will post -0.64 EPS for the current year.

Several large investors have recently made changes to their positions in the company. BlueCrest Capital Management Ltd raised its stake in shares of Cerecor by 15.5% in the first quarter. BlueCrest Capital Management Ltd now owns 33,300 shares of the company’s stock worth $194,000 after buying an additional 4,471 shares during the period. BlackRock Inc. raised its stake in shares of Cerecor by 18.5% in the fourth quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock worth $109,000 after buying an additional 5,293 shares during the period. Northern Trust Corp raised its stake in shares of Cerecor by 47.9% in the fourth quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock worth $65,000 after buying an additional 6,500 shares during the period. Vanguard Group Inc raised its stake in shares of Cerecor by 10.1% in the third quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock worth $411,000 after buying an additional 8,094 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Cerecor in the first quarter worth about $60,000. 53.94% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently commented on CERC. TheStreet cut Cerecor from a “c-” rating to a “d+” rating in a research note on Wednesday, May 29th. HC Wainwright set a $11.00 target price on Cerecor and gave the stock a “buy” rating in a research note on Wednesday, April 17th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $8.00 target price on shares of Cerecor in a research note on Monday, May 13th. ValuEngine cut Cerecor from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Maxim Group reissued a “buy” rating and issued a $10.00 target price on shares of Cerecor in a research note on Friday, May 10th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.67.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/insider-buying-cerecor-inc-nasdaqcerc-major-shareholder-buys-10000-shares-of-stock/3041566.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Featured Article: Technical Analysis

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.